1
|
Sahbudin I, Singh R, Trickey J, Baranskaya A, Tracy A, Raza K, Filer A, Jowett S, Boonen A. Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review. Rheumatol Adv Pract 2023; 7:rkad040. [PMID: 37197378 PMCID: PMC10185403 DOI: 10.1093/rap/rkad040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 03/12/2023] [Indexed: 05/19/2023] Open
Abstract
Objective Early treatment of RA improves clinical outcomes; however, the impact on health economic outcomes is unclear. This review sought to investigate the relationship between symptom/disease duration and resource utilization/costs and the responsiveness of costs following RA diagnosis. Methods A systematic search was performed on Pubmed, EMBASE, CINAHL and Medline. Studies were eligible if patients were DMARD-naïve and fulfilled 1987 ACR or 2010 ACR/EULAR RA classification criteria. Studies had to report symptom/disease duration and resource utilization or direct/indirect costs as health economic outcomes. The relationships between symptom/disease duration and costs were explored. Results Three hundred and fifty-seven records were identified in a systematic search; nine were eligible for analysis. The mean/median of symptom/disease duration in studies ranged between 25 days and 6 years. Annual direct costs of RA following diagnosis showed a U-shaped distribution in two studies. Longer symptom duration before starting a DMARD (>180 days) was associated with lower health-care utilization in the first year of RA diagnosis in one study. Annual direct and indirect costs 6 months before RA diagnosis were higher in patients with shorter symptom duration (<6 months) in one study. Given the clinical and methodological heterogeneities, the association between symptom/disease duration and costs after diagnosis was not computed. Conclusion The association between symptom/disease duration at the time of DMARD initiation and resource utilization/cost in patients with RA remains unclear. Health economic modelling with clearly defined symptom duration, resource utilization and long-term productivity is vital to address this evidence gap.
Collapse
Affiliation(s)
- Ilfita Sahbudin
- Correspondence to: Ilfita Sahbudin, Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2WB, UK. E-mail:
| | | | - Jeanette Trickey
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Aliaksandra Baranskaya
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Alexander Tracy
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Karim Raza
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
- Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, UK
| | - Andrew Filer
- Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Sue Jowett
- Health Economics Unit, Institute for Applied Health Research, University of Birmingham, Birmingham, UK
| | - Annelies Boonen
- Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
- Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
2
|
Brouwer R, ten Klooster PM, Masselink JB, Vonkeman HE. Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients. Pharmacol Res Perspect 2022; 10:e01025. [PMID: 36479936 PMCID: PMC9731312 DOI: 10.1002/prp2.1025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 10/18/2022] [Accepted: 10/21/2022] [Indexed: 12/13/2022] Open
Abstract
The objective of this study was to examine the maintenance of effect and safety after a hospital-wide switch for economic reasons from adalimumab originator Humira® to biosimilar Amgevita® in real-world rheumatoid arthritis (RA) patients and patient satisfaction with the switch. We conducted a single-center retrospective observational study of RA patients on the course of their disease activity (DAS28, ESR, and CRP), health-related quality of life (SF-36), and functional disability (HAQ-DI) before and up to 1 year after the switch, supplemented with a cross-sectional survey on satisfaction and experienced side effects approximately 18 months after the switch. Treatment outcomes were analyzed with linear mixed modeling and generalized estimating equations. Of 52 RA patients sufficient data were available. Disease activity levels, the proportion of patients in remission, and SF-36 and HAQ-DI scores did not significantly change from before the switch. Overall, patients were satisfied with the switch. Three patients (7.9%) stopped the biosimilar due to side effects. In conclusion, switching to the adalimumab biosimilar did not result in increased disease activity or worse patient-reported outcomes. Also, there was no apparent evidence of increased side effects. Patients themselves were mostly satisfied with the switching experience.
Collapse
Affiliation(s)
- Rianne Brouwer
- Department of Rheumatology and Clinical ImmunologyMedisch Spectrum TwenteEnschedeThe Netherlands
| | - Peter M. ten Klooster
- Department of Psychology, Health and TechnologyUniversity of TwenteEnschedeThe Netherlands
| | - Joost B. Masselink
- Department of Clinical PharmacyMedisch Spectrum TwenteEnschedeThe Netherlands
| | - Harald E. Vonkeman
- Department of Rheumatology and Clinical ImmunologyMedisch Spectrum TwenteEnschedeThe Netherlands
- Department of Psychology, Health and TechnologyUniversity of TwenteEnschedeThe Netherlands
| |
Collapse
|
3
|
Zhao WM, Wang ZJ, Shi R, Zhu YY, Zhang S, Wang RF, Wang DG. Environmental factors influencing the risk of ANCA-associated vasculitis. Front Immunol 2022; 13:991256. [PMID: 36119110 PMCID: PMC9479327 DOI: 10.3389/fimmu.2022.991256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 08/19/2022] [Indexed: 11/13/2022] Open
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases characterized by inflammation and destruction of small and medium-sized blood vessels. Clinical disease phenotypes include microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The incidence of AAV has been on the rise in recent years with advances in ANCA testing. The etiology and pathogenesis of AAV are multifactorial and influenced by both genetic and environmental factors, as well as innate and adaptive immune system responses. Multiple case reports have shown that sustained exposure to silica in an occupational environment resulted in a significantly increased risk of ANCA positivity. A meta-analysis involving six case-control studies showed that silica exposure was positively associated with AAV incidence. Additionally, exposure to air pollutants, such as carbon monoxide (CO), is a risk factor for AAV. AAV has seasonal trends. Studies have shown that various environmental factors stimulate the body to activate neutrophils and expose their own antigens, resulting in the release of proteases and neutrophil extracellular traps, which damage vascular endothelial cells. Additionally, the activation of complement replacement pathways may exacerbate vascular inflammation. However, the role of environmental factors in the etiology of AAV remains unclear and has received little attention. In this review, we summarized the recent literature on the study of environmental factors, such as seasons, air pollution, latitude, silica, and microbial infection, in AAV with the aim of exploring the relationship between environmental factors and AAV and possible mechanisms of action to provide a scientific basis for the prevention and treatment of AAV.
Collapse
|
4
|
Marques ML, Alunno A, Boonen A, Ter Wee MM, Falzon L, Ramiro S, Putrik P. Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. RMD Open 2021; 7:rmdopen-2020-001522. [PMID: 33542048 PMCID: PMC7868290 DOI: 10.1136/rmdopen-2020-001522] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 01/06/2021] [Accepted: 01/14/2021] [Indexed: 12/12/2022] Open
Abstract
Objective To summarise the methodological aspects in studies with work participation (WP) as outcome domain in inflammatory arthritis (IA) and other chronic diseases. Methods Two systematic literature reviews (SLRs) were conducted in key electronic databases (2014–2019): search 1 focused on longitudinal prospective studies in IA and search 2 on SLRs in other chronic diseases. Two reviewers independently identified eligible studies and extracted data covering pre-defined methodological areas. Results In total, 58 studies in IA (22 randomised controlled trials, 36 longitudinal observational studies) and 24 SLRs in other chronic diseases were included. WP was the primary outcome in 26/58 (45%) studies. The methodological aspects least accounted for in IA studies were as follows (proportions of studies positively adhering to the topic are shown): aligning the studied population (16/58 (28%)) and sample size calculation (8/58 (14%)) with the work-related study objective; attribution of WP to overall health (28/58 (48%)); accounting for skewness of presenteeism/sick leave (10/52 (19%)); accounting for work-related contextual factors (25/58 (43%)); reporting attrition and its reasons (1/58 (2%)); reporting both aggregated results and proportions of individuals reaching predefined meaningful change or state (11/58 (16%)). SLRs in other chronic diseases confirmed heterogeneity and methodological flaws identified in IA studies without identifying new issues. Conclusion High methodological heterogeneity was observed in studies with WP as outcome domain. Consensus around various methodological aspects specific to WP studies is needed to improve quality of future studies. This review informs the EULAR Points to Consider for conducting and reporting studies with WP as an outcome in IA.
Collapse
Affiliation(s)
- Mary Lucy Marques
- Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands .,Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal
| | - Alessia Alunno
- Rheumatology Unit, University of Perugia Department of Medicine, Perugia, Umbria, Italy
| | - Annelies Boonen
- Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Limburg, The Netherlands.,Department of Health Services Research, Universiteit Maastricht Care and Public Health Research Institute, Maastricht, Limburg, The Netherlands
| | - Marieke M Ter Wee
- Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.,Department of Rheumatology and immunology, AI&I, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Louise Falzon
- Center for Personalized Health, Feinstein Institutes for Medical Research, Northwell Health, New York, New York, USA
| | - Sofia Ramiro
- Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.,Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, The Netherlands
| | - Polina Putrik
- Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Limburg, The Netherlands.,Department of Health Services Research, Universiteit Maastricht Care and Public Health Research Institute, Maastricht, Limburg, The Netherlands
| |
Collapse
|
5
|
Tatangelo M, Tomlinson G, Paterson JM, Keystone E, Bansback N, Bombardier C. Health care costs of rheumatoid arthritis: A longitudinal population study. PLoS One 2021; 16:e0251334. [PMID: 33956894 PMCID: PMC8101709 DOI: 10.1371/journal.pone.0251334] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 04/23/2021] [Indexed: 01/11/2023] Open
Abstract
Quantifying the contribution of rheumatoid arthritis to the acquisition of subsequent health care costs is an emerging focus of the rheumatologic community and payers of health care. Our objective was to determine the healthcare costs before and after diagnosis of rheumatoid arthritis (RA) from the public payer's perspective. The study design was a longitudinal observational administrative data-based cohort with RA cases from Ontario Canada (n = 104,933) and two control groups, matched 1:1 on year of cohort entry from 2001 to 2016. The first control group was matched on age, sex and calendar year of cohort entry (diagnosis year for those with RA); the second group added medical history to the match before RA diagnosis year. The main exposure was new onset RA. The secondary exposure was calendar year of RA diagnosis to compare attributable costs over the study observation window. Main outcomes were health care costs in 2015 Canadian dollars, overall and by cost category. We used attribution methods to classify costs into those associated with RA, those associated with comorbidities, and age/sex-related underlying costs. Health care costs associated with RA increased up to the year of diagnosis, where they reached $8,591: $4,142 in RA associated costs; $1,242 in RA comorbidity associated costs; and $3,207 in underlying costs. In the eighth-year post diagnosis, the RA costs declined to $2,567 while the RA comorbidity associated costs remained relatively constant at $1,142, and the underlying age/sex related cost increased to $4,426. RA patients had lower costs when diagnosed in later calendar years. Our results suggest a large proportion of disease related health care costs are a result of costs associated with RA comorbidities, which may appear many years before diagnosis.
Collapse
Affiliation(s)
- Mark Tatangelo
- University of Toronto, Toronto, Ontario, Canada
- University Health Network, Toronto, Ontario, Canada
| | - George Tomlinson
- University of Toronto, Toronto, Ontario, Canada
- University Health Network, Toronto, Ontario, Canada
| | - J Michael Paterson
- University of Toronto, Toronto, Ontario, Canada
- ICES, Toronto, Ontario, Canada
| | | | - Nick Bansback
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Claire Bombardier
- University of Toronto, Toronto, Ontario, Canada
- University Health Network, Toronto, Ontario, Canada
| |
Collapse
|
6
|
Roodenrijs NMT, Welsing PMJ, van der Goes MC, Tekstra J, Lafeber FPJG, Jacobs JWG, van Laar JM. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology (Oxford) 2021; 60:4681-4690. [PMID: 33502493 DOI: 10.1093/rheumatology/keab078] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 12/21/2020] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES To determine the impact of difficult-to-treat rheumatoid arthritis (D2T RA) on (costs related to) healthcare utilization, other resource use and work productivity. METHODS Data regarding healthcare utilization, other resource use and work productivity of 52 D2T (according to the EULAR definition) and 100 non-D2T RA patients were collected via a questionnaire and an electronic patient record review during a study visit. Annual costs were calculated and compared between groups. Multivariable linear regression analysis was performed to assess whether having D2T RA was associated with higher costs. RESULTS Mean (95% CI) annual total costs were €37 605 (€27 689 - €50 378) for D2T and €19 217 (€15 647 - €22 945) for non-D2T RA patients (P<0.001). D2T RA patients visited their rheumatologist more frequently, were more often admitted to day-care facilities, underwent more laboratory tests and used more drugs (specifically targeted synthetic DMARDs), compared with non-D2T RA patients (P<0.01). In D2T RA patients, the main contributors to total costs were informal help of family and friends (28%), drugs (26%) and loss of work productivity (16%). After adjustment for physical functioning (HAQ), having D2T RA was no longer statistically significantly associated with higher total costs. HAQ was the only independent determinant of higher costs in multivariable analysis. CONCLUSIONS The economic burden of D2T RA is significantly higher than that of non-D2T RA, indicated by higher healthcare utilization and higher annual total costs. Functional disability is a key determinant of higher costs in RA.
Collapse
Affiliation(s)
- Nadia M T Roodenrijs
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Paco M J Welsing
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Marlies C van der Goes
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht.,Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands
| | - Janneke Tekstra
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Floris P J G Lafeber
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Johannes W G Jacobs
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht
| | - Jacob M van Laar
- Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht
| |
Collapse
|
7
|
Jung JY, Kim JW, Kim HA, Suh CH. Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2019; 19:979-986. [PMID: 31498682 DOI: 10.1080/14712598.2019.1665018] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by long-standing inflammation in multiple joints. Rituximab, a monoclonal antibody, which binds to CD20, is effective in suppressing disease activity and preventing joint damage in RA. CT-P10 was developed as a biosimilar of rituximab and approved for use to treat hematologic malignancies and immune diseases including RA. Area covered: This article describes the need for this biosimilar and summarizes the non-clinical studies verifying the physicochemical and biologic similarities and the clinical studies confirming the clinical similarity of CT-P10 to rituximab in patients with RA. Expert opinion: CT-P10 had been evaluated and proven the efficacy and safety in RA in Phase I and III randomized controlled trial with extension studies including a switching regimen. Therefore, CT-P10 is recommended in the treatment of RA.
Collapse
Affiliation(s)
- Ju-Yang Jung
- Department of Rheumatology, Ajou University School of Medicine , Suwon , Korea
| | - Ji-Won Kim
- Department of Rheumatology, Ajou University School of Medicine , Suwon , Korea
| | - Hyoun-Ah Kim
- Department of Rheumatology, Ajou University School of Medicine , Suwon , Korea
| | - Chang-Hee Suh
- Department of Rheumatology, Ajou University School of Medicine , Suwon , Korea
| |
Collapse
|
8
|
Romão VC, Fonseca JE. Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder? Front Med (Lausanne) 2019; 6:144. [PMID: 31294026 PMCID: PMC6606708 DOI: 10.3389/fmed.2019.00144] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 06/10/2019] [Indexed: 12/17/2022] Open
Affiliation(s)
- Vasco C Romão
- Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal.,Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - João Eurico Fonseca
- Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal.,Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| |
Collapse
|
9
|
Johnson BK, Bahçe-Altuntaş A. Too Little Too Late: Effect of Poor Access to Biologics for Patients with Rheumatoid Arthritis. J Rheumatol 2019; 44:1765-1766. [PMID: 29196544 DOI: 10.3899/jrheum.171148] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Beverly K Johnson
- Assistant Professor of Medicine, Albert Einstein College of Medicine, Director of Rheumatology, Jacobi Medical Center and North Central Bronx (NCB) Hospital;
| | - Asena Bahçe-Altuntaş
- Assistant Professor of Medicine, Albert Einstein College of Medicine, Director of the Joint Pain Clinic, Jacobi/NCB, New York, New York, USA
| |
Collapse
|
10
|
Chen KC, Wu CH, Tang CH, Huang KC. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database. PLoS One 2018; 13:e0200758. [PMID: 30020997 PMCID: PMC6051649 DOI: 10.1371/journal.pone.0200758] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 05/18/2018] [Indexed: 11/18/2022] Open
Abstract
Objectives This nationwide population-based study aimed at evaluating healthcare resource utilization and direct medical costs among rheumatoid arthritis (RA) patients receiving biologic therapies in Taiwan. Design and setting A retrospective cohort of 2,425 RA patients who had received first-line tumor necrosis factor (TNF)-α antagonist treatment for at least 6 months (the baseline period) between 2007 and 2011 was identified from the National Health Insurance Research Database in Taiwan. Outcome measures Healthcare resource utilization and direct medical costs of those patients were analyzed and compared 1 year before the index date and during the 1-year follow-up. Results Analytical results demonstrated that 87.7% of RA patients received the same TNF-α antagonist during the 1-year follow-up, 2.4% of the patients switched to another TNF-α antagonist after the baseline period, 7.1% of the study cohort received a second-line biologic agent, while the remaining patients discontinued use of any TNF-α antagonist. Compared to 1 year before the index date, there were significant reductions in emergency room visits and hospitalization days for RA patients treated with the same TNF-α antagonist during the 1-year follow-up. However, there was an increase of outpatient visits among those patients. For those RA patients who switched to another TNF-α antagonist or received a second-line biologic agent, they consumed more healthcare resources. Furthermore, the corresponding medication costs went up markedly during the 1-year follow-up, but nearly all total direct medical costs (biologics excluded) were significantly reduced across the study cohort. Lastly, male patients incurred slightly higher medical costs than their counterparts, albeit in a statistically insignificant fashion. Conclusions This investigation revealed that RA patients treated with biologics utilized fewer emergency room visits and shorter hospitalization days, but incurred higher costs. In summary, this study provides meaningful information on healthcare resource utilization and medical costs of RA patients for healthcare providers and policymakers.
Collapse
Affiliation(s)
- Kuan-Chen Chen
- School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan
- Department of Health Care Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
| | - Chu-Hua Wu
- School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan
| | - Chao-Hsiun Tang
- School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan
- * E-mail: (KCH); (CHT)
| | - Kuo-Cherh Huang
- School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan
- * E-mail: (KCH); (CHT)
| |
Collapse
|
11
|
Husberg M, Bernfort L, Hallert E. Costs and disease activity in early rheumatoid arthritis in 1996-2000 and 2006-2011, improved outcome and shift in distribution of costs: a two-year follow-up. Scand J Rheumatol 2018; 47:378-383. [PMID: 29611446 DOI: 10.1080/03009742.2017.1420224] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
OBJECTIVE To evaluate changes in healthcare utilization, costs, and disease activity from 1996 to 2011 for patients with early rheumatoid arthritis (RA). METHOD Two cohorts of patients with early RA, included in 1996-1998 (T1) and 2006-2009 (T2), were followed regularly. Healthcare utilization, costs, and disease activity were compared between cohorts during 2 years after diagnosis. RESULTS Disease activity was significantly improved in T2 vs T1. Drug costs increased in T2 vs T1 (EUR 911 vs EUR 535, respectively; p = 0.017), and costs for RA-related hospitalization decreased. More than 90% in T2 were prescribed disease-modifying anti-rheumatic drugs (DMARDs) at inclusion compared to 50% in T1. At 2 year follow-up, levels were still > 90% in T2, while corresponding values in T1 were just above 70%. Comparing T2 to T1, total direct costs were slightly higher in T2 (EUR 3941 vs EUR 3364, respectively; ns), sick leave decreased (EUR 3511 vs EUR 5672; p = 0.025), while disability pension increased slightly (EUR 4889 vs EUR 4244; ns), but total indirect costs remained unchanged (EUR 8400 vs EUR 9916; ns). Total direct and indirect costs did not differ between the cohorts (EUR 12 342 in T2 vs EUR 13 280 in T1; ns), and loss of productivity still represented the largest component of total costs. CONCLUSION T2 patients were prescribed DMARDs earlier and more aggressively than T1 patients. Stable and better improvements in disease activity, function, and quality of life were achieved in T2 compared to T1. There was a shift within the components in direct costs and indirect costs, but total costs remained essentially unchanged.
Collapse
Affiliation(s)
- M Husberg
- a Center for Medical Technology Assessment, Division of Health Care Analysis , Linköping University , Linköping , Sweden
| | - L Bernfort
- a Center for Medical Technology Assessment, Division of Health Care Analysis , Linköping University , Linköping , Sweden
| | - E Hallert
- a Center for Medical Technology Assessment, Division of Health Care Analysis , Linköping University , Linköping , Sweden
| |
Collapse
|
12
|
Sundström K. Cost of Illness for Five Major Foodborne Illnesses and Sequelae in Sweden. APPLIED HEALTH ECONOMICS AND HEALTH POLICY 2018; 16:243-257. [PMID: 29313242 PMCID: PMC5874275 DOI: 10.1007/s40258-017-0369-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVES The main objective of this study was to derive cost estimates of five major foodborne illnesses (campylobacteriosis, salmonellosis, enterohemorrhagic Escherichia coli (EHEC), yersiniosis and shigellosis) in Sweden. These estimates provide a necessary contribution to perform future cost-benefit analyses aimed at reducing the burden of foodborne disease. A secondary aim was to obtain estimates of the true number of cases that occur in the community, thus providing necessary ground for calculating costs. METHODS The true number of cases for each foodborne illness was simulated by multiplying the reported number of cases by sequential multipliers, one for each potential source of information loss about a case. This assessment of the true number of cases was then used to estimate the number of cases of sequelae for each illness. An incidence-based analysis was then used to calculate direct medical and non-medical costs, as well as indirect costs. Data for estimating the true number of cases for each illness were primarily based on an expert panel, while the derivation of costs mainly utilized national registries, databases and published literature. RESULTS The estimated number of cases was between 7- and 11-fold higher than the reported number of cases, indicating the importance of taking information loss into account when calculating costs. By far the most common pathogen of the five was campylobacter, with an estimated 101,719 (90% credibility interval [CI] 59,640-158,025) human cases occurring annually. For salmonella, 19,678 (90% CI 8394-40,456) cases were estimated to occur each year, while the other three pathogens were less common, with a yearly incidence of approximately 2500-5500 cases each. The total cost for the five pathogens (including sequelae) amounted to €142 million annually. Campylobacter was the most costly pathogen, representing 69% of the total costs. Salmonellosis and EHEC constituted 18 and 9% of these costs, respectively, while yersiniosis and shigellosis represented approximately 2% each. Costs for sequelae were significant and accounted for approximately 50% of the total costs. CONCLUSIONS Our simulations indicated that campylobacter infection was more common and more costly than salmonella, EHEC, yersinia and shigella combined. Estimated costs for all illnesses were highly influenced by (1) considering potential information losses about cases in the population (which increased costs 7- to 11-fold), and (2) taking account of post-infection sequelae (which doubled the costs).
Collapse
Affiliation(s)
- Kristian Sundström
- AgriFood Economics Centre, Lund University, Scheelevägen 15 D, 223 63, Lund, Sweden.
| |
Collapse
|
13
|
Kiadaliri AA, Englund M. Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998-2015. Clin Rheumatol 2018; 37:825-830. [PMID: 29359231 PMCID: PMC5835057 DOI: 10.1007/s10067-018-3983-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 01/05/2018] [Accepted: 01/09/2018] [Indexed: 12/05/2022]
Abstract
Hospitalization is an important component of rheumatoid arthritis (RA) and gout economic burden. This study aimed to assess temporal trends and regional disparities in RA and gout hospitalizations among people aged ≥ 20 years in Sweden during 1998–2015. Data on hospital admissions with a principal diagnosis of RA or gout were collected from the National Patient Register. Age-standardized hospitalization rates (ASHRs) were calculated by means of direct standardization. The absolute and relative regional disparities were assessed. The temporal trends in ASHR and proportion of RA and gout hospitalizations from all and musculoskeletal disorders hospitalizations were analyzed using joinpoint regression. Between 1998–2000 and 2013–2015, the ASHR for RA declined by 78.9% from 109.9 to 23.2 per 100,000 Swedish adults, while it almost doubled for gout (from 10.5 to 20.8 per 100,000 Swedish adults). While in 1998–2000, RA hospitalizations were 10.3 times more frequent than gout (0.54 vs 0.05% of all hospitalizations), this ratio declined to 1.1 in 2013–2015 (0.13 vs 0.11% of all hospitalizations). The joinpoint regression revealed that, on average, the ASHR for RA declined by 10.2% (95% CI: 9.3–11.1) per year whereas for gout, it rose by 4.3% (3.2–5.4) per year during 1998–2015. While the relative regional disparities were stable, the absolute regional disparity declined for RA and increased for gout over the study period. While substantial decline in RA hospitalization is encouraging, the substantial rise in gout hospitalization is of concern, reflecting potential increase in prevalence of gout and suboptimal management of the disease.
Collapse
Affiliation(s)
- Aliasghar A Kiadaliri
- Lund University, Faculty of Medicine, Department of Clinical Sciences-Lund, Orthopaedics, Clinical Epidemiology Unit, Lund, Sweden.
- Skåne University Hospital, Clinical Epidemiology Unit, Remissgatan 4, SE-221 85, Lund, Sweden.
| | - Martin Englund
- Lund University, Faculty of Medicine, Department of Clinical Sciences-Lund, Orthopaedics, Clinical Epidemiology Unit, Lund, Sweden
- Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, USA
| |
Collapse
|
14
|
Coiffier B. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. Expert Rev Clin Pharmacol 2017; 10:923-933. [DOI: 10.1080/17512433.2017.1359537] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Bertrand Coiffier
- Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| |
Collapse
|
15
|
Bansback N, Fu E, Sun H, Guh D, Zhang W, Lacaille D, Milbers K, Anis AH. Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis. Curr Rheumatol Rep 2017; 19:54. [DOI: 10.1007/s11926-017-0680-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
16
|
Yin H, Pizzol M, Xu L. External costs of PM2.5 pollution in Beijing, China: Uncertainty analysis of multiple health impacts and costs. ENVIRONMENTAL POLLUTION (BARKING, ESSEX : 1987) 2017; 226:356-369. [PMID: 28410806 DOI: 10.1016/j.envpol.2017.02.029] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 02/02/2017] [Accepted: 02/14/2017] [Indexed: 05/18/2023]
Abstract
Some cities in China are facing serious air pollution problems including high concentrations of particles, SO2 and NOx. Exposure to PM2.5, one of the primary air pollutants in many cities in China, is highly correlated with various adverse health impacts and ultimately represents a cost for society. The aim of this study is to assess health impacts and external costs related to PM2.5 pollution in Beijing, China with different baseline concentrations and valuation methods. The idea is to provide a reasonable estimate of the total health impacts and external cost due to PM2.5 pollution, as well as a quantification of the relevant uncertainty. PM2.5 concentrations were retrieved for the entire 2012 period in 16 districts of Beijing. The various PM2.5 related health impacts were identified and classified to avoid double counting. Exposure-response coefficients were then obtained from literature. Both the value of statistical life (VSL) and the amended human capital (AHC) approach were applied for external costs estimation, which could provide the upper and lower bound of the external costs due to PM2.5. To fully understand the uncertainty levels, the external cost distribution was determined via Monte Carlo simulation based on the uncertainty of the parameters such as PM2.5 concentration, exposure-response coefficients, and economic cost per case. The results showed that the external costs were equivalent to around 0.3% (AHC, China's guideline: C0 = 35 μg/m3) to 0.9% (VSL, WHO guideline: C0 = 10 μg/m3) of regional GDP depending on the valuation method and on the assumed baseline PM2.5 concentration (C0). Among all the health impacts, the economic loss due to premature deaths accounted for more than 80% of the overall external costs. The results of this study could help policymakers prioritizing the PM2.5 pollution control interventions and internalize the external costs through the application of economic policy instruments.
Collapse
Affiliation(s)
- Hao Yin
- State Key Laboratory of Environmental Simulation and Pollution Control, School of Environment, Beijing Normal University, No. 19, Xinjiekouwai Street, Haidian District, Beijing 100875, China; Department of Development and Planning, Danish Centre for Environmental Assessment, Aalborg University, Rendsburggade 14, 9000 Aalborg, Denmark
| | - Massimo Pizzol
- Department of Development and Planning, Danish Centre for Environmental Assessment, Aalborg University, Rendsburggade 14, 9000 Aalborg, Denmark
| | - Linyu Xu
- State Key Laboratory of Environmental Simulation and Pollution Control, School of Environment, Beijing Normal University, No. 19, Xinjiekouwai Street, Haidian District, Beijing 100875, China.
| |
Collapse
|
17
|
Husberg M, Davidson T, Hallert E. Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart. Clin Rheumatol 2017; 36:499-506. [PMID: 27832385 PMCID: PMC5323479 DOI: 10.1007/s10067-016-3470-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Revised: 10/28/2016] [Accepted: 10/30/2016] [Indexed: 01/14/2023]
Abstract
The aim of the present study was to calculate non-medical costs during year 1 after diagnosis in two cohorts of patients with early rheumatoid arthritis enrolled 1996-1998 and 2006-2009. Clinical data were collected regularly in both cohorts. Besides information about healthcare utilization and days lost from work, patients reported non-medical costs for aids/devices, transportation, formal and informal care. Formal care was valued as full labour cost for official home help (€42.80/h) and informal care from relatives and friends as opportunity cost of leisure time, corresponding to 35% of labour cost (€15/h). In both cohorts, only 2% used formal care, while more than 50% used informal care. Prescription of aids/devices was more frequent in cohort 2 and more women than men needed aids/devices. Help with transportation was also more common in cohort 2. Women in both cohorts needed more informal care than men, especially with personal care and household issues. Adjusting for covariates in regression models, female sex remained associated with higher costs in both cohorts. Non-medical costs in cohort 2 were €1892, €1575 constituting informal care, corresponding to 83% of non-medical costs. Total non-medical costs constituted 25% of total direct costs and 11% of total direct and indirect costs. Informal care accounted for the largest part of non-medical costs and women had higher costs than men. Despite established social welfare system, it is obvious that family and friends, to a large extent, are involved in informal care of patients with early RA, and this may underestimate the total burden of the disease.
Collapse
Affiliation(s)
- Magnus Husberg
- Center for Medical Technology Assessment, Department of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden
| | - Thomas Davidson
- Center for Medical Technology Assessment, Department of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden
| | - Eva Hallert
- Center for Medical Technology Assessment, Department of Medical and Health Sciences, Linköping University, SE-58183, Linköping, Sweden.
| |
Collapse
|
18
|
Løppenthin K, Esbensen BA, Østergaard M, Ibsen R, Kjellberg J, Jennum P. Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study. Clin Rheumatol 2016; 36:517-525. [DOI: 10.1007/s10067-016-3446-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 10/03/2016] [Accepted: 10/04/2016] [Indexed: 12/19/2022]
|
19
|
Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. Rheumatology (Oxford) 2016; 55:1803-11. [PMID: 27354689 DOI: 10.1093/rheumatology/kew264] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE The aim of this study was to explore the cost-effectiveness of biological DMARDs (bDMARDs) compared with conventional synthetic DMARDs (csDMARDs) for RA using real-world data from Finnish registers. METHODS RA patients starting their first bDMARD and comparator patients using csDMARDs during 2007-11 were obtained from the National register of biologic treatments in Finland and the Jyväskylä Central Hospital patient records. Propensity score matching was applied to adjust for differences between bDMARD and csDMARD users. Effectiveness was measured in quality-adjusted life years (QALY) and based on the register of biologic treatments in Finland and Jyväskylä Central Hospital patient records, whereas the direct costs were obtained from relevant Finnish national registers. Patients were followed up for 2 years, and both costs and effectiveness for the second year were discounted at 3%. The incremental cost-effectiveness ratio (ICER) with 95% CI was calculated based on bootstrapped mean costs and effectiveness. RESULTS Of 1581 RA patients meeting study inclusion criteria, 552 bDMARD and 220 csDMARD users were included in analyses after matching. Mean costs for bDMARDs and csDMARDs were €55 371 and €24 879, while mean effectiveness was 1.23 and 1.20 QALYs, respectively. Consequent ICER was €902 210/QALY. Results were confirmed in sensitivity analyses. CONCLUSION The high incremental cost and the small, non-significant difference in effectiveness resulted in high ICER, suggesting that bDMARDs are not cost-effective. Regardless of matching, latent confounders may introduce bias to the results.
Collapse
Affiliation(s)
| | | | - Pasi Aronen
- Faculty of Pharmacy, University of Helsinki, Helsinki
| | - Tuulikki Sokka
- Department of Rheumatology, Jyväskylä Central Hospital, Jyväskylä
| | - Kari Puolakka
- Department of Medicine, South Karelia Central Hospital, Lappeenranta
| | - Riitta Tuompo
- Department of Medicine, Helsinki University Central Hospital, Helsinki
| | - Markku Korpela
- Centre for Rheumatic Diseases, Tampere University Hospital, Tampere
| | - Mikko Vasala
- Department of Internal Medicine, Kainuu Central Hospital, Kajaani
| | - Kirsti Ilva
- Department of Medicine, Kanta-Häme Central Hospital, Hämeenlinna
| | - Dan Nordström
- Department of Medicine, Helsinki University Central Hospital, Helsinki Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - Marja Blom
- Faculty of Pharmacy, University of Helsinki, Helsinki
| |
Collapse
|
20
|
van der Valk ME, Mangen MJJ, Severs M, van der Have M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, van der Woude CJ, Romberg-Camps MJL, Clemens CHM, Jansen JM, van de Meeberg PC, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk C, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. PLoS One 2016; 11:e0142481. [PMID: 27099937 PMCID: PMC4839678 DOI: 10.1371/journal.pone.0142481] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Accepted: 10/22/2015] [Indexed: 02/05/2023] Open
Abstract
Background With the increasing use of anti-TNF therapy in inflammatory bowel disease (IBD), a shift of costs has been observed with medication costs replacing hospitalization and surgery as major cost driver. We aimed to explore the evolution of IBD-related costs over two years of follow-up. Methods and Findings In total 1,307 Crohn's disease (CD) patients and 915 ulcerative colitis (UC) patients were prospectively followed for two years by three-monthly web-based questionnaires. Changes of healthcare costs, productivity costs and out-of-pocket costs over time were assessed using mixed model analysis. Multivariable logistic regression analysis was used to identify costs drivers. In total 737 CD patients and 566 UC were included. Total costs were stable over two years of follow-up, with annual total costs of €7,835 in CD and €3,600 in UC. However, within healthcare costs, the proportion of anti-TNF therapy-related costs increased from 64% to 72% in CD (p<0.01) and from 31% to 39% in UC (p < 0.01). In contrast, the proportion of hospitalization costs decreased from 19% to 13% in CD (p<0.01), and 22% to 15% in UC (p < 0.01). Penetrating disease course predicted an increase of healthcare costs (adjusted odds ratio (adj. OR) 1.95 (95% CI 1.02–3.37) in CD and age <40 years in UC (adj. OR 4.72 (95% CI 1.61–13.86)). Conclusions BD-related costs remained stable over two years. However, the proportion of anti-TNF-related healthcare costs increased, while hospitalization costs decreased. Factors associated with increased costs were penetrating disease course in CD and age <40 in UC.
Collapse
Affiliation(s)
- Mirthe E. van der Valk
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Marie-Josée J. Mangen
- Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Mirjam Severs
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Mike van der Have
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Gerard Dijkstra
- Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, the Netherlands
| | - Ad A. van Bodegraven
- Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, the Netherlands
- Department of Internal Medicine. Gastroenterology and Geriatrics, Atrium-Orbis Medical Centre, Heerlen-Sittard-Geleen, the Netherlands
| | - Herma H. Fidder
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Dirk J. de Jong
- Department of Gastroenterology and Hepatology, Radboud University Medical Centre Nijmegen, Nijmegen, the Netherlands
| | - C. Janneke van der Woude
- Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, the Netherlands
| | - Mariëlle J. L. Romberg-Camps
- Department of Internal Medicine. Gastroenterology and Geriatrics, Atrium-Orbis Medical Centre, Heerlen-Sittard-Geleen, the Netherlands
| | - Cees H. M. Clemens
- Department of Gastroenterology and Hepatology, Diaconessenhuis, Leiden, the Netherlands
| | - Jeroen M. Jansen
- Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands
| | - Paul C. van de Meeberg
- Department of Gastroenterology and Hepatology, Slingeland Hospital, Doetinchem, the Netherlands
| | - Nofel Mahmmod
- Department of Gastroenterology and Hepatology, Antonius Hospital, Nieuwegein, the Netherlands
| | | | - Cyriel Y. Ponsioen
- Department of Gastroenterology and Hepatology, Academic Medical Centre Amsterdam, Amsterdam, the Netherlands
| | - Clemens Bolwerk
- Department of Gastroenterology and Hepatology, Reinier de Graaf Groep, Delft, the Netherlands
| | - J. Reinoud Vermeijden
- Department of Gastroenterology and Hepatology, Meander Medical Centre, Amersfoort, the Netherlands
| | - Peter D. Siersema
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Max Leenders
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
| | - Bas Oldenburg
- Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands
- * E-mail:
| | | |
Collapse
|
21
|
Beck M, Michel B, Rybarczyk-Vigouret MC, Sordet C, Sibilia J, Velten M. Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings? Eur J Hosp Pharm 2016; 24:85-90. [PMID: 31156910 DOI: 10.1136/ejhpharm-2016-000904] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 03/03/2016] [Accepted: 03/07/2016] [Indexed: 12/30/2022] Open
Abstract
Objectives Biosimilar infliximab, the first similar biological medicinal product containing monoclonal antibodies to be commercialised, is likely to contribute to a significant reduction in healthcare costs. We aimed to assess the cost savings potential over 1 year of the use of biosimilar infliximab for the treatment of rheumatoid arthritis (RA) patients in Alsace and in France, in a real-life setting. Methods The analysis was based on a previously conducted observational study which evaluated the annual cost of the care of patients with RA treated with biological therapies in 2012 in Alsace. Average annual costs to manage RA patients were calculated, taking into account the decrease in the retail price between 2012 and 2015 (as given in the official national price list) and the local negotiated price for biosimilar infliximab. Annual cost savings for different biosimilar prescription scenarios were calculated using 2015 prices. Results Management of RA patients with biosimilar infliximab was significantly cheaper than with adalimumab or etanercept (€11 907 vs €12 981 and €13 551, respectively). The projected annual cost savings reached €13.6 million nationally, if all adult RA patients treated with the originator infliximab switched to the biosimilar drug. These savings, if fully reallocated for the treatment of RA, would enable the treatment of 1141 additional patients. Conclusions The study showed a positive financial impact of introducing biosimilar infliximab for the treatment of RA patients in France. Such savings could contribute to improved patient care by allowing more patients to be treated without more money being spent.
Collapse
Affiliation(s)
- M Beck
- OMEDIT Alsace, Agence Régionale de Santé d'Alsace, Strasbourg, France
| | - B Michel
- OMEDIT Alsace, Agence Régionale de Santé d'Alsace, Strasbourg, France.,Service de Pharmacie-Stérilisation, C.H.R.U. Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | - C Sordet
- Service de Rhumatologie, C.H.R.U. Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - J Sibilia
- Service de Rhumatologie, C.H.R.U. Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - M Velten
- Laboratoire d'épidémiologie et de santé publique-EA3430, Faculté de Médecine, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
22
|
Wang BCM, Hsu PN, Furnback W, Ney J, Yang YW, Fang CH, Tang CH. Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database. Drugs Real World Outcomes 2016; 3:107-114. [PMID: 27747810 PMCID: PMC4819475 DOI: 10.1007/s40801-016-0063-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of the joints. OBJECTIVES This research aims to estimate the economic burden of RA in Taiwan. METHODS The National Health Insurance Research Database (NHIRD), a claims-based dataset encompassing 99 % of Taiwan's population, was applied. We used a micro-costing approach for direct healthcare costs and indirect social costs by estimating the quantities and prices of cost categories. Direct costs included surgeries, hospitalizations, medical devices and materials, laboratory tests, and drugs. The costs and quantities of the direct economic burden were calculated based on 2011 data of NHIRD. We identified RA patients and a control cohort matched 1:4 on demographic and clinical covariates to calculate the incremental cost related to RA. Indirect costs were evaluated by missed work (absenteeism) and worker productivity (presenteeism). For the indirect burden, we estimated the rate of absenteeism and presenteeism from a patient survey. Costs were presented in US dollars (US$1 = 30 TWD). RESULTS A total of 41,269 RA patients were included in the database with incremental total direct cost of US$86,413,971 and indirect cost of US$138,492,987. This resulted in an average incremental direct cost of US$2050 per RA patient. Within direct costs, the largest burdens were associated with drugs (US$73,028,944), laboratory tests (US$6,132,395), and hospitalizations (US$3,208,559). For indirect costs, absenteeism costs and presenteeism costs were US$16,059,681 and US$114,291,687, respectively. CONCLUSIONS The economic burden of RA in Taiwan is driven by indirect healthcare costs, most notably presenteeism.
Collapse
Affiliation(s)
- Bruce C M Wang
- Elysia Group Ltd., Floor 2, No. 17-1, Lane 113, Xiamen Street, Taipei, Taiwan
| | - Ping-Ning Hsu
- National Taiwan University, No. 1, Changde St., Zhongzheng Dist., Taipei, 10048, Taiwan
| | - Wesley Furnback
- Elysia Group Ltd., Floor 2, No. 17-1, Lane 113, Xiamen Street, Taipei, Taiwan
| | - John Ney
- University of Washington, 1410 NE Campus Parkway, Seattle, WA, 98195, USA
| | - Ya-Wen Yang
- Pfizer Limited, 177 Chung Cheng East Road, sec. 2, Tansui, New Taipei City, 251, Taiwan
| | - Chi-Hui Fang
- Pfizer Limited, 177 Chung Cheng East Road, sec. 2, Tansui, New Taipei City, 251, Taiwan
| | - Chao-Hsiun Tang
- Taipei Medical University, 250 Wuxing Street, Taipei, 110, Taiwan.
| |
Collapse
|
23
|
Hallert E, Husberg M, Kalkan A, Bernfort L. Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996–98 and 2006–09. Scand J Rheumatol 2016; 45:371-8. [DOI: 10.3109/03009742.2015.1126344] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- E Hallert
- Centre for Medical Technology Assessment, Division of Health Care Analysis, Linköping University, Linköping, Sweden
| | - M Husberg
- Centre for Medical Technology Assessment, Division of Health Care Analysis, Linköping University, Linköping, Sweden
| | - A Kalkan
- Centre for Medical Technology Assessment, Division of Health Care Analysis, Linköping University, Linköping, Sweden
| | - L Bernfort
- Centre for Medical Technology Assessment, Division of Health Care Analysis, Linköping University, Linköping, Sweden
| |
Collapse
|
24
|
Peschken CA, Hitchon CA, Garland A, Bernstein CN, Chen H, Fransoo R, Marrie RA. A Population-based Study of Intensive Care Unit Admissions in Rheumatoid Arthritis. J Rheumatol 2015; 43:26-33. [PMID: 26628597 DOI: 10.3899/jrheum.150312] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/14/2015] [Indexed: 01/22/2023]
Abstract
OBJECTIVE We aimed to determine the incidence of and mortality after critical illness in rheumatoid arthritis (RA) compared with the general population, and to describe the risks for and characteristics of critical illness in patients with RA. METHODS We used population-based administrative data from the Data Repository at the Manitoba Centre for Health Policy from 1984 to 2010, and linked clinical data from an intensive care unit (ICU) database to identify all persons with RA in the province requiring ICU admission. We identified a population-based control group, matched by age, sex, socioeconomic status, and region of residence. The incidence of ICU admission, reasons for, and mortality after ICU admission were compared between populations using age- and sex-standardized rates, rate ratios, Cox proportional hazards models, and logistic regression models. RESULTS We identified 10,078 prevalent and 5560 incident cases of RA. After adjustment, the risk for ICU admission was higher for RA (HR 1.65, 95% CI 1.50-1.83) versus the matched general population. From 2000-2010, the annual incidence of ICU admission among prevalent patients was about 1% in RA, with a crude 10-year incidence of 8%. Compared with the general population admitted to ICU, 1 year after ICU admission, mortality was increased by 40% in RA. Cardiovascular disorders were the most common reason for ICU admission in RA. CONCLUSION Patients with RA have a higher risk for admission to the ICU than the general population and increased mortality 1 year after admission. Even with advances in management, RA remains a serious disease with significant morbidity.
Collapse
Affiliation(s)
- Christine A Peschken
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba.
| | - Carol A Hitchon
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba
| | - Allan Garland
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba
| | - Charles N Bernstein
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba
| | - Hui Chen
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba
| | - Randy Fransoo
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba
| | - Ruth Ann Marrie
- From the Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, and the IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada.C.A. Peschken, MD, MSc, FRCPC, Associate Professor, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A. Garland, MD, MA, Department of Internal Medicine, and Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba;C.N. Bernstein, MD, Department of Internal Medicine, and IBD Clinical and Research Centre, University of Manitoba; H. Chen, MSc, Manitoba Centre for Health Policy, University of Manitoba; R. Fransoo, PhD, Department of Community Health Sciences, and Manitoba Centre for Health Policy, University of Manitoba; R.A. Marrie, MD, PhD, Department of Internal Medicine, and Department of Community Health Sciences, University of Manitoba
| |
Collapse
|
25
|
Larsson I, Fridlund B, Arvidsson B, Teleman A, Svedberg P, Bergman S. A nurse-led rheumatology clinic versus rheumatologist-led clinic in monitoring of patients with chronic inflammatory arthritis undergoing biological therapy: a cost comparison study in a randomised controlled trial. BMC Musculoskelet Disord 2015; 16:354. [PMID: 26573936 PMCID: PMC4647492 DOI: 10.1186/s12891-015-0817-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Accepted: 11/13/2015] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Recommendations for rheumatology nursing management of chronic inflammatory arthritis (CIA) from European League Against Rheumatism (EULAR) states that nurses should take part in the monitoring patients' disease and therapy in order to achieve cost savings. The aim of the study was to compare the costs of rheumatology care between a nurse-led rheumatology clinic (NLC), based on person-centred care (PCC), versus a rheumatologist-led clinic (RLC), in monitoring of patients with CIA undergoing biological therapy. METHODS Patients with CIA undergoing biological therapy (n = 107) and a Disease Activity Score of 28 ≤ 3.2 were randomised to follow-up by either NLC or RLC. All patients met the rheumatologist at inclusion and after 12 months. In the intervention one of two annual monitoring visits in an RLC was replaced by a visit to an NLC. The primary outcome was total annual cost of rheumatology care. RESULTS A total of 97 patients completed the RCT at the 12 month follow-up. Replacing one of the two annual rheumatologist monitoring visits by a nurse-led monitoring visit, resulted in no additional contacts to the rheumatology clinic, but rather a decrease in the use of resources and a reduction of costs. The total annual rheumatology care costs including fixed monitoring, variable monitoring, rehabilitation, specialist consultations, radiography, and pharmacological therapy, generated € 14107.7 per patient in the NLC compared with € 16274.9 in the RCL (p = 0.004), giving a € 2167.2 (13 %) lower annual cost for the NLC. CONCLUSIONS Patients with CIA and low disease activity or in remission undergoing biological therapy can be monitored with a reduced resource use and at a lower annual cost by an NLC, based on PCC with no difference in clinical outcomes. This could free resources for more intensive monitoring of patients early in the disease or patients with high disease activity. TRIAL REGISTRATION The trial is registered as a clinical trial at the ClinicalTrials.gov (NCT01071447). Registration date: October 8, 2009.
Collapse
Affiliation(s)
- Ingrid Larsson
- School of Health and Welfare, Halmstad University, Box 823, S-30118, Halmstad, Sweden.
- Spenshult Research and Development Centre, Halmstad, Sweden.
| | - Bengt Fridlund
- School of Health and Welfare, Jönköping University, Jönköping, Sweden
| | - Barbro Arvidsson
- School of Health and Welfare, Halmstad University, Box 823, S-30118, Halmstad, Sweden
| | | | - Petra Svedberg
- School of Health and Welfare, Halmstad University, Box 823, S-30118, Halmstad, Sweden
| | - Stefan Bergman
- School of Health and Welfare, Halmstad University, Box 823, S-30118, Halmstad, Sweden
- Spenshult Research and Development Centre, Halmstad, Sweden
- Primary Health Care Unit, Department of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
26
|
Hallert E, Husberg M, Kalkan A, Rahmqvist M, Skogh T, Bernfort L. Changes in sociodemographic characteristics at baseline in two Swedish cohorts of patients with early rheumatoid arthritis diagnosed 1996-98 and 2006-09. Scand J Rheumatol 2014; 44:100-5. [PMID: 25352338 DOI: 10.3109/03009742.2014.930926] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES To compare baseline sociodemographic characteristics in two rheumatoid arthritis (RA) cohorts enrolled 10 years apart, and to examine differences with respect to the general population. METHOD Clinical and sociodemographic data were collected in 320 early RA patients during 1996-98 (TIRA-1) and 467 patients in 2006-09 (TIRA-2). Multivariate logistic regression tests were performed and intercohort comparisons were related to general population data, obtained from official databases. RESULTS TIRA-2 patients were older than TIRA-1 (58 vs. 56 years). Women (both cohorts, 67%) were younger than men in TIRA-1 (55 vs. 59 years) and in TIRA-2 (57 vs. 61 years). Disease activity was similar but TIRA-2 women scored worse pain and worse on the HAQ. Approximately 73% were cohabiting, in both cohorts and in the general population. Education was higher in TIRA-2 than in TIRA-2 but still lower than in the general population. Women had consistently higher education than men. Education was associated with age, younger patients having higher education. In both cohorts, lower education was associated with increased disability pension and increased sick leave. Sick leave was lower in TIRA-2 than in TIRA-1 (37% vs. 50%) but disability pension was higher (16% vs. 10%). In TIRA-1, 9% of women had disability pension compared with 17% in TIRA-2. A similar decrease in sick leave and an increase in disability pension were also seen in the general population. Older age and a higher HAQ score were associated with increased sick leave and being in the TIRA-2 cohort was associated with decreased sick leave. CONCLUSIONS TIRA-2 patients were slightly older, better educated, had lower sick leave and higher disability pension than those in TIRA-1. Similar changes were seen simultaneously in the general population. Belonging to the TIRA-2 cohort was associated with decreased sick leave, indicating that societal changes are of importance.
Collapse
Affiliation(s)
- E Hallert
- Centre for Medical Technology Assessment, Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University , Linköping , Sweden
| | | | | | | | | | | |
Collapse
|
27
|
Small-molecule inhibitors for autoimmune arthritis: success, failure and the future. Eur J Pharmacol 2014; 747:200-5. [PMID: 25220243 DOI: 10.1016/j.ejphar.2014.08.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2014] [Revised: 08/21/2014] [Accepted: 08/24/2014] [Indexed: 12/13/2022]
Abstract
Treatment of patients with aggressive autoimmune arthritis, such as rheumatoid arthritis (RA), is a considerable challenge for physicians, particularly rheumatologists. Because of the nature of autoimmune arthritis, effective and complete suppression of disease activity has been the primary therapeutic goal. Although currently available disease-modifying antirheumatic drugs (DMARDs) can successfully control the disease progression in a large proportion of patients, the benefit/risk ratio is not very much satisfied. The introduction of biologic agents such as anti-tumor necrosis factor-α, anti-interleukin-6, and anti-CD20 brings significant help to those patients with an inadequate response to treatment with DMARDs. In considering the limitation of currently available DMARDs and biologics, the development of new DMARDs, small-molecule inhibitors (SMIs), has recently emerged. In the past few years, a great volume of knowledge has been revealed from the experience of examining the usefulness of several SMIs for therapeutics of autoimmune arthritis. This paper addresses the up-to-date knowledge regarding autoimmune arthritis, therapeutics, findings from recently developed SMIs and the benefits and drawbacks of the development of SMIs. In addition, perspectives on the future development of SMIs for autoimmune arthritis will be described and discussed.
Collapse
|